Cadrenal Therapeutics, Inc. reported financial results for Q3 2025, highlighting progress in tecarfarin’s clinical development and the acquisition of frunexian. Research and development expenses were $0.7 million, general and administrative expenses were $2.0 million, resulting in a net loss of $2.7 million. The company had cash and cash equivalents of $3.9 million on September 30, 2025.

Cadrenal Therapeutics focuses on developing anticoagulants to address gaps in current therapy. They have two clinical-stage assets, tecarfarin and frunexian, designed to provide better anticoagulation with fewer bleeding complications. The company aims to reshape standards of care in anticoagulation by targeting underserved patient populations.

The company’s CEO, Quang X. Pham, emphasized the importance of progressing tecarfarin into clinical applications with significant anticoagulation challenges. Cadrenal is in discussions with key partners to develop a strategy critical for addressing gaps in care and unlocking value for shareholders. The company’s balance sheet for September 30, 2025, shows total assets of $4,087,622 and total liabilities of $1,352,675.

In Q3 2025, Cadrenal reported a net loss of $2.7 million, with research and development expenses at $0.7 million and general and administrative expenses at $2.0 million. The company had cash and cash equivalents of $3.9 million on September 30, 2025. Cadrenal is focused on developing novel anticoagulants to bridge gaps in current therapy and reshape standards of care in anticoagulation.

Read more at GlobeNewswire: Cadrenal Therapeutics Reports Third Quarter 2025 Financial